Molecular Characterization of Plasma HDL, LDL, and VLDL Lipids Cargos from Atherosclerotic Patients with Advanced Carotid Lesions: A Preliminary Report

Int J Mol Sci. 2022 Oct 18;23(20):12449. doi: 10.3390/ijms232012449.

Abstract

Carotid atherosclerosis represents a relevant healthcare problem, since unstable plaques are responsible for approximately 15% of neurologic events, namely transient ischemic attack and stroke. Although statins treatment has proven effective in reducing LDL-cholesterol and the onset of acute clinical events, a residual risk may persist suggesting the need for the detection of reliable molecular markers useful for the identification of patients at higher risk regardless of optimal medical therapy. In this regard, several lines of evidence show a relationship among specific biologically active plasma lipids, atherosclerosis, and acute clinical events. We performed a Selected Reaction Monitoring-based High Performance Liquid Chromatography-tandem Mass Spectrometry (SRM-based HPLC-MS/MS) analysis on plasma HDL, LDL, and VLDL fractions purified, by isopycnic salt gradient ultracentrifugation, from twenty-eight patients undergoing carotid endarterectomy, having either a "hard" or a "soft" plaque, with the aim of characterizing the specific lipidomic patterns associated with features of carotid plaque instability. One hundred and thirty lipid species encompassing different lipid (sub)classes were monitored. Supervised multivariate analysis showed that lipids belonging to phosphatidylethanolamine (PE), sphingomyelin (SM), and diacylglycerol (DG) classes mostly contribute to discrimination within each lipoprotein fraction according to the plaque typology. Differential analysis evidenced a significant dysregulation of LDL PE (38:6), SM (32:1), and SM (32:2) between the two groups of patients (adj. p-value threshold = 0.05 and log2FC ≥ |0.58|). Using this approach, some LDL-associated markers of plaque vulnerability have been identified, in line with the current knowledge of the key roles of these phospholipids in lipoprotein metabolism and cardiovascular disease. This proof-of-concept study reports promising results, showing that lipoprotein lipidomics may present a valuable approach for identifying new biomarkers of potential clinical relevance.

Keywords: carotid atherosclerosis; lipoproteins; phosphatidylethanolamine; plaque vulnerability; sphingomyelin; targeted lipidomics.

MeSH terms

  • Atherosclerosis*
  • Biomarkers
  • Cholesterol
  • Diglycerides
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors*
  • Lipoproteins
  • Lipoproteins, LDL
  • Phosphatidylethanolamines
  • Phospholipids
  • Plaque, Atherosclerotic*
  • Sphingomyelins
  • Tandem Mass Spectrometry

Substances

  • Phosphatidylethanolamines
  • Diglycerides
  • Sphingomyelins
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipoproteins
  • Phospholipids
  • Cholesterol
  • Biomarkers
  • Lipoproteins, LDL

Grants and funding

A.J.L.: G.N., and M.F. thank the University of Sassari (Fondo di Ateneo per la Ricerca 2020) and the Fondazione di Sardegna (BANDO FONDAZIONE DI SARDEGNA 2022 E 2023—PROGETTI DI RICERCA DI BASE DIPARTIMENTALI (D.R.16/2022)) for their financial support. G.N. thanks “Programma Operativo Nazionale (PON) Ricerca e Innovazione 2014–2020—Asse I “Capitale Umano”, Azione I.2—A.I.M. Attraction and International Mobility, Linea 1 Mobilità dei ricercatori, AIM1874325-3, CUP: J54I18000110001”, and “Fondazione di Sardegna 2018–2020 and 2021—Progetti di Ricerca di Base Dipartimentali (D.R. 2397/2021)” for their financial support.